EUCTR2015-004985-27-NL进行中（未招募）1 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens
HOVON Foundation0 个研究点开始时间: 2016年6月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of symptomatic CLL (according to IWCLL guidelines)
- •Patients without prior treatment for CLL
- •(Corticoid treatment administered due to necessary immediate intervention is allowed; within the last 10 days before start of study treatment only dose equivalents of maximum 20 mg prednisolone are permitted;
- •Patients aged = 18 years, not fit for FCR-like regimens, according to the treating physician;
- •Able to adhere to the study visit schedule and other protocol requirements;
- •WHO performance status of = 2
- •Laboratory test results within these ranges:
- •- absolute neutrophil count = 1.0 x 109/l and, platelet count and = 50 x 109/l
- •unless due to bone marrow infiltration,
- •- creatinine clearance = 45 ml/min .(using 24-hour creatinine clearance or modified Cockcroft-Gault equation
- •- total bilirubin = 1,5 x ULN unless considered due to Gilbert’s syndrome,
- •- transaminases = 3 x ULN;
- •Negative serum or urine pregnancy test within 28 days prior to registration (all females of childbearing potential);
- •Written informed consent
- •Patient is capable of giving informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Current inclusion in other clinical trials
- •Intolerance of exogenous protein administration;
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Known sensitivity or allergy to murine products.
- •Positive hepatitis serology (serology testing required at screening), as follows:
- •-Hepatitis B virus (HBV): Patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc).
- •-Hepatitis C virus (HCV): Patients with positive hepatitis C serology unless HCV- (RNA) is confirmed negative.
- •HIV positive patients;
- •Active fungal, bacterial, and/or viral infection that requires systemic therapy; Note: active controlled as well as chronice/recurrent infections are at risk of reactivation/infection during teatment with obinutuzumab and/or venetoclax);
- •Vaccination with a live vaccine a minimum of 28 days prior to registration.
- •Use of any other experimental drug or therapy within 28 days of baseline;
- •Concurrent use of other anti-cancer agents or treatments;
- •History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:
- •-Malignancies surgically treated with curative intent and with no known active disease present for
- •3 years before randomization
- •-Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •-Adequately treated cervical carcinoma in situ without evidence of disease
- •Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease) (CTCAE grade III-IV);
- •Severe pulmonary dysfunction (CTCAE grade III-IV);
- •Severe neurological or psychiatric disease (CTCAE grade III-IV);
- •Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, hypertension, hyperthyroidism or hypothyroidism etc.)
- •Women who are pregnant or lactating;
- •Fertile men or women of childbearing potential unless: (1). surgically sterile or = 2 years after the onset of menopause (2). willing to use a highly effective contraceptive method (Pearl Index <1) such as oral contraceptives, intrauterine device, sexual abstinence or barrier method of contraception in conjunction with spermicidal jelly during study treatment and in female patients for 18 months after end of antibody treatment and male patients for 6 months after end of treatment.
- •Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
研究者
相似试验
招募中
2 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial)10024324Chronic Lymphocytic LeukemiaCLLNL-OMON54803HOVO70
已完成
4 期
A study to compare the effectiveness of Alpecin liquid & Minoxdil 5% in the management of male pattern baldness(Hair loss).CTRI/2014/07/004768Fullife Healthcare Pvt Ltd210
进行中（未招募）
1 期
A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic kidney cancer (BERAT study)metastatic renal cell carcinoma (mRCC)MedDRA version: 18.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2011-005939-78-DECESAR Central European Society for Anticancer Drug Research-EWIV
尚未招募
4 期
MeRethon RCTCTRI/2021/08/035665Meril Life Sciences Pvt Ltd
尚未招募
不适用
Comparison of the Clear Coajet Hemostatic effect on EMR and ESDKCT0007744The Catholic University of Korea, Yeouido St. Mary's Hospital404